The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019
The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006
Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Source: Eur Respir J 2006; 28: Suppl. 50, 128s Year: 2006
Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis Source: Eur Respir J, 55 (1) 1901181; 10.1183/13993003.01181-2019 Year: 2020
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017
Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003
Factors preventing better treatment completion among MDR TB cases in a rich-resource setting Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015